Swiss pharma expansion

Solutia Inc.’s Pharmaceutical Services Division (Solutia PSD) will construct a
facility for the synthesis of highly potent Active Pharmaceutical Ingredients (APIs). The new facility will be based at Solutia PSD’s existing site in Marly, Switzerland. The expansion will provide pharmaceutical companies with an important resource enabling the contract manufacture of highly potent drugs to be carried out to the highest standards of quality and efficiency. Commissioning of the new facility is planned for first quarter, 2003.
Oncology remains the largest area of unmet clinical need in pharmaceutical research, says Ed Robinson, president of Solutia PSD.

Previous articleHalliburton moving HQ to Houston
Next articleHigh-temperature grade tubing
Stainless Steel World is part of The KCI Media Group, a group of companies focused on building and sustaining global communities in the flow control industries. We publish news on a daily basis and connect business-to-business professionals through our online communities, publications, conferences and exhibitions.